Riferminogene pecaplasmide

N/A

Report date: 2024/09/26 15:34:00

Base Information

Drug NameRiferminogene pecaplasmide

Drug Alias NameDNA-based delivery of Fibroblast Growth Factor 1 (FGF-1)Cardiovascular therapeutic proteinCardiovascular gene therapyFGF-1 gene therapyriferminogene pecaplasmid +[8]

ClassificationCell and gene therapy > Gene therapy > Plasmid

Mechanisms of ActionFGF1 gene transferenceAngiogenesis inducers

TargetsFibroblast growth factor 1

Therapy Area/IndicationsPeripheral Vascular DiseasesPeripheral Arterial DiseaseArterial Occlusive Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumCanada +[32]

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesFresh Tracks Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSanofi

Active IndicationsN/A

Inactive IndicationsPeripheral Vascular DiseasesPeripheral Arterial DiseaseArterial Occlusive Diseases

Other Information

ATC CodeN/A